EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)

Hisato Kawakami iD, Koki Nakanishi, Akitaka Makiyama, Hirotaka Konishi, Satoshi Morita, Yukiya Narita, Naotoshi Sugimoto, Keiko Minashi, Motohiro Imano, Rin Inamoto, Yasuhiro Kodera, Hiroki Kume und 4 weitere

Gastric Cancer · 2025-01 · 28 (1) · 51-61

DOI: 10.1007/s10120-024-01555-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, online erschienen am 10.10.2024. Verfasst von Hisato Kawakami und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan. kawakami_h@med.kindai.ac.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab-deruxtecan (T-DXd) was approved for the treatment of HER2-positive patients with advanced gastric cancer in Japan based on the results of the DESTINY-Gastric01 trial. This study aimed to collect real-world data and evaluate the effectiveness and safety of T-DXd.

Methods

Patients aged ≥ 20 years at the start of T-DXd administration with a histopathologically confirmed diagnosis of HER2-positive unresectable advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma that had worsened after chemotherapy were enrolled in this retrospective cohort study. Key outcomes included T-DXd treatment status, overall survival (OS), real-world progression-free survival (rwPFS), time to treatment failure (TTF), objective response rate and frequency of grade ≥ 3 adverse events (AEs).

Results

Of the 312 patients included in the analysis, 75.3% were male, the median (range) age was 70.0 (27.0–89.0) years, 12.2% had an ECOG PS ≥ 2, 43.3% had ascites and the initial T-DXd dose was > 5.4– ≤ 6.4 mg/kg in 78.2% of patients. The median (95% confidence interval) OS, rwPFS and TTF (months) was 8.9 (8.0–11.0), 4.6 (4.0–5.1) and 3.9 (3.4–4.2), respectively. The response rate was 42.9% in patients with a target lesion. In total, 48.4% of patients experienced a grade ≥ 3 AE, 2.6% experienced grade 5 AEs and 60.9% experienced AEs leading to T-DXd dose adjustments (reduction: 36.9%, interruption: 34.0% or discontinuation: 23.7%). No new safety signals were detected.

Conclusions

T-DXd was effective and had a manageable safety profile as a third- or later-line treatment for patients with HER2-positive gastric or GEJ cancer in Japanese clinical practice. Clinical trial registration: UMIN000049032

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesAged, 80 and overJapanCamptothecinAdenocarcinomaEast Asian PeopleImmunoconjugates

Stichwörter der Autor:innen

EffectivenessGastric cancerHER2-positiveJapanPost-marketing surveillanceReal worldSafetyThird- or later-lineTrastuzumab-deruxtecan (T-DXd)

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCamptothecinImmunoconjugatesERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan. kawakami_h@med.kindai.ac.jp.
  • Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Cancer Center, Gifu University Hospital, Gifu, Japan.
  • Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

ORCID-Profile: Hisato Kawakami

Förderung

  • Daiichi-Sankyo

Zitieren

APA

Kawakami, H., Nakanishi, K., Makiyama, A., Konishi, H., Morita, S., Narita, Y., Sugimoto, N., Minashi, K., Imano, M., Inamoto, R., Kodera, Y., Kume, H., Yamaguchi, K., Hashimoto, W., Muro, K., & EN-DEAVOR Study Group (2025). Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer, 28(1), 51-61. https://doi.org/10.1007/s10120-024-01555-w

Vancouver

Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, et al. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer. 2025;28(1):51-61. doi:10.1007/s10120-024-01555-w

BibTeX
@article{Kawakami2025,
  author = {Kawakami, Hisato and Nakanishi, Koki and Makiyama, Akitaka and Konishi, Hirotaka and Morita, Satoshi and Narita, Yukiya and Sugimoto, Naotoshi and Minashi, Keiko and Imano, Motohiro and Inamoto, Rin and Kodera, Yasuhiro and Kume, Hiroki and Yamaguchi, Keita and Hashimoto, Wataru and Muro, Kei and EN-DEAVOR Study Group, EN-DEAVOR Study Group},
  title = {Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)},
  journal = {Gastric Cancer},
  year = {2025},
  volume = {28},
  number = {1},
  pages = {51--61},
  doi = {10.1007/s10120-024-01555-w}
}
Kostenlos starten →